Wellness & Lifestyle

Sotatercept in High-Risk Pulmonary Arterial Hypertension: A Landmark Advance in Patient Outcomes

By MedXY 08/02/2025

Sotatercept significantly reduces the risk of death, lung transplantation, or hospitalization in high-risk pulmonary arterial hypertension patients, marking a major advance in the management of this life-threatening disease.

Clinical Updates Wellness & Lifestyle

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY 08/02/2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.

Clinical Updates Wellness & Lifestyle

Navigational Bronchoscopy Versus Transthoracic Needle Biopsy for Peripheral Lung Nodules: New Evidence from the VERITAS Trial

By MedXY 08/02/2025

Navigational bronchoscopy offers noninferior diagnostic accuracy to transthoracic needle biopsy for peripheral pulmonary nodules, with notably fewer pneumothorax complications.

Clinical Updates Wellness & Lifestyle

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

By MedXY 08/01/2025

A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.

Clinical Updates Wellness & Lifestyle

Trimethoprim–Sulfamethoxazole in Pregnancy: No Impact on Birth Weight in a Zimbabwean RCT

By MedXY 08/01/2025

A large randomized trial in Zimbabwe found that trimethoprim–sulfamethoxazole prophylaxis during pregnancy did not significantly increase birth weight or reduce adverse outcomes.

Clinical Updates Wellness & Lifestyle

Durable Efficacy and Long-term Safety of AAV Gene Therapy in Severe Hemophilia B: 13-Year Follow-up Results

By MedXY 08/01/2025

A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.

Clinical Updates Wellness & Lifestyle

Nerandomilast for Idiopathic and Progressive Pulmonary Fibrosis: Phase 3 Trial Insights

By MedXY 08/01/2025

Phase 3 trials demonstrate that nerandomilast, a selective PDE4B inhibitor, significantly slows lung function decline in idiopathic and progressive pulmonary fibrosis over 52 weeks, with manageable safety profiles.

Clinical Updates Wellness & Lifestyle

Corynebacterium diphtheriae Outbreak among Migrants in Europe: Clinical, Epidemiologic, and Microbiologic Insights

By MedXY 08/01/2025

A multicountry outbreak of diphtheria among migrants in Europe raised concerns about cutaneous and respiratory disease, cross-border spread, and emerging antibiotic resistance. Genomic analysis revealed multiclonal transmission and resistance challenges for standard therapies.

Clinical Updates Wellness & Lifestyle

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

By MedXY 08/01/2025

Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.

Clinical Updates Wellness & Lifestyle

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY 08/01/2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.